Testing a new scan for breast cancer before treatment
Part of Cancer, Skin clinical trials.
This trial uses a special PET/CT scan to find breast cancer cells that have a certain marker (CD73). It may help doctors see the cancer more clearly before you start other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman at least 18 years old.
- You have not yet had radiation therapy or chemotherapy.
- Your doctor expects you to live at least 12 more weeks.
- You have at least one tumor that can be measured on a scan.
- Your liver and kidneys are working well (no severe problems).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This trial tests a new imaging test (a special PET scan) that can see HER2 proteins in breast cancer tumors. It is for people who are already getting treatment before surgery to see if the scan helps doctors understand how well the therapy is working.
This Phase 1 study tests a new PET/CT imaging tracer to see how well it can detect breast cancer spots in the body. It may help doctors learn where breast cancer is and how imaging could work better in the future.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.